DISEASE CERVICAL CANCER WORLD HEALTH PROBLEM

ELECTRON FOTOGRAPHS OF PAPILLOMAVIRUS RESPONSIBLE FOR CERVICAL CANCER

Pan American Health Organization INFECTED PEOPLE WITH PAPILLOMAVIRUS: cases of invasive cervical cancer 10 millon of High grade lesions 30 millon of Low grade lesions 300 millon cases of infected people with papillomavirus GRAN SUBREGISTRO: 5 o 6 de cada MILLON PERSONS

NATURAL HISTORY OF CERVICAL CANCER ETIOPATOGENIA OF CERVICAL NEOPLASIA

Social Health Problem It is very important to consider that, when a women gets infected with papillomavirus and develop cervical cancer, this condition have a very high cost in their families as well for the Health System. Because treatment requires a very high infraestructure and high price drugs. In many cases in develop countries woman is the responsible for the maintenance of the family. This situation makes even more expensive the social cost generated for this disease.

CERVICAL CANCER SOLUTION

Vaccinia Virus MVA Excellent antigen presentation Estimulates the Immne system very efficiently

MVA E2 Healing Therapy JUNE 2015CONFIDENCIAL CERVICAL CANCER

EXAMPLES OF LESIONS TREATED WITH MVA E2

Rosales, C. Cancer Immunology Immunotherapy. (2000) MVA E2 eliminates Tumor in rabbits

C V1-B V1-A Fig 2

Patient Number Week 0Week 4 Week 8Week 12 Figure 3

Patient Number Week 0Week 14 Figure 2

Larynx lesions

Conventional treatments according to the lesion to be treated TREATMENTCOSTRESULTS CRYOSURGERY: ELIMATION OF LESIONS B FREEZING WITH NO USD ELIMINATES LESIONS BUT RECURRENCES ARE VERY OFTEN DOES NOT ELIMATES PAPILLOMAVIRUS CHIMIOTHERAPY: CHEMICAL DRUGS USED TO INHIBIT TUMOR GROWTH 20, ,000 USD 50 % EFFICACY DOES NOT ELIMINATES PAPILLOMAVIRUS CONIZATION: ELIMINATION OF LESION BY SURGERY PROCEDURES USD ELIMATES LESIONS BUT RECURRENCES APPEAR DOES NOT ELIMINATES PAPILLOMAVIRUS RADIOTHERAPY: USE OF RADIATIONS TO DESTROY TUMOR CELLS 25, ,000 USD 50 % EFFICACY DOES NOT ELIMINATES PAPILLOMAVIRUS MVA E2 500 USA 95 % RFFICACY ELIMINATES PAPILLOMAVIRUS COMPARATIVE COST IN TREATMENTS

1. MVA E2 IS CAPABLE OF ELIMINATE ALL LESIONS GENERATED BY PAPILLOMAVIRUS 2. MVA E2 GENERATES ANTIBODIES AND CITOTOXIC CELLS AGAINST TUMOR CELL BEARING PAPILLOMAVIRUS 3. MVA E2 ELIMINATES PAPILLOMAVIRUS FROM INFECTED-PATIENTS CONCLUSION FROM CLINICAL TRIALS PHASE I, II AND III

References